Ablation Device - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Ablation Device

The Experts below are selected from a list of 1419 Experts worldwide ranked by ideXlab platform

Ablation Device – Free Register to Access Experts & Abstracts

Jack W Jennings – One of the best experts on this subject based on the ideXlab platform.

  • Combination acetabular radiofrequency Ablation and cementoplasty using a navigational radiofrequency Ablation Device and ultrahigh viscosity cement: technical note
    Skeletal Radiology, 2016
    Co-Authors: Adam N. Wallace, Ambrose J Huang, Devin Vaswani, Randy O. Chang, Jack W Jennings
    Abstract:

    Background Percutaneous radiofrequency Ablation and cementoplasty is an alternative palliative therapy for painful metastases involving axial load-bearing bones. This technical report describes the use of a navigational radiofrequency probe to ablate acetabular metastases from an anterior approach followed by instillation of ultrahigh viscosity cement under CT-fluoroscopic guidance. Materials and methods The tumor Ablation databases of two institutions were retrospectively reviewed to identify patients who underwent combination acetabular radiofrequency Ablation and cementoplasty using the STAR Tumor Ablation and StabiliT Vertebral Augmentation Systems (DFINE; San Jose, CA). Pre-procedure acetabular tumor volume was measured on cross-sectional imaging. Pre- and post-procedure pain scores were measured using the Numeric Rating Scale (10-point scale) and compared. Partial pain improvement was categorically defined as ≥ 2-point pain score reduction. Patients were evaluated for evidence of immediate complications. Electronic medical records were reviewed for evidence of delayed complications. Results During the study period, 12 patients with acetabular metastases were treated. The median tumor volume was 54.3 mL (range, 28.3–109.8 mL). Pre- and post-procedure pain scores were obtained from 92 % (11/12) of the cohort. The median pre-procedure pain score was 8 (range, 3–10). Post-procedure pain scores were obtained 7 days (82 %; 9/11), 11 days (9.1 %; 1/11) or 21 days (9.1 %; 1/11) after treatment. The median post-treatment pain score was 3 (range, 1–8), a statistically significant difference compared with pre-treatment ( P  = 0.002). Categorically, 73 % (8/11) of patients reported partial pain relief after treatment. No immediate symptomatic complications occurred. Three patients (25 %; 3/12) were discharged to hospice within 1 week of treatment. No delayed complications occurred in the remaining 75 % (9/12) of patients during median clinical follow-up of 62 days (range, 14–178 days). Conclusions Palliative percutaneous acetabular radiofrequency Ablation and cementoplasty can be feasibly performed from an anterior approach using a navigational Ablation probe and ultrahigh viscosity cement instilled under CT-fluoroscopic guidance.

  • combination acetabular radiofrequency Ablation and cementoplasty using a navigational radiofrequency Ablation Device and ultrahigh viscosity cement technical note
    Skeletal Radiology, 2016
    Co-Authors: Adam N. Wallace, Ambrose J Huang, Devin Vaswani, Randy O. Chang, Jack W Jennings
    Abstract:

    Background Percutaneous radiofrequency Ablation and cementoplasty is an alternative palliative therapy for painful metastases involving axial load-bearing bones. This technical report describes the use of a navigational radiofrequency probe to ablate acetabular metastases from an anterior approach followed by instillation of ultrahigh viscosity cement under CT-fluoroscopic guidance.

  • treatment of metastatic posterior vertebral body osseous tumors by using a targeted bipolar radiofrequency Ablation Device technical note
    Radiology, 2014
    Co-Authors: Travis J Hillen, Praveen Anchala, Michael V Friedman, Jack W Jennings
    Abstract:

    The articulating radiofrequency Ablation Device provides access to posterior vertebral body tumors that were difficult to access previously by using conventional Ablation Devices and allows for safe and controlled Ablation of posterior vertebral body tumors without thermal nerve injury.

Kanji Kawachi – One of the best experts on this subject based on the ideXlab platform.

  • Novel tumor-Ablation Device for liver tumors utilizing heat energy generated under an alternating magnetic field.
    Journal of gastroenterology and hepatology, 2008
    Co-Authors: Koichi Sato, Yuji Watanabe, Atsushi Horiuchi, Shungo Yukumi, Takashi Doi, Motohira Yoshida, Yuji Yamamoto, Tsunehiro Maehara, Takashi Naohara, Kanji Kawachi
    Abstract:

    We have developed a novel tumor-Ablation Device for liver tumors utilizing heat energy induced by magnesium ferrite (MgFe(2)O(4)) particles under an alternating magnetic field (AMF) produced by electric currents. This novel Device can repeatedly heat liver tumors at lower temperature than usual heating Devices, such as radiofrequency Ablation therapy, with slight infliction of pain. This study assesses its heating effect on rat liver tumors as local therapy. The small needle was manufactured from MgFe(2)O(4) particles by sintering at 1100 degrees C. After a MgFe(2)O(4) needle was inserted into liver tumors comprising of dRLh-84 cells, the tumors were heated for 30 min under an AMF. We examined cellular activity by using nicotinamide adenine dinucleotide (NADH) diaphorase staining and terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick-end labeling (TUNEL) staining, and evaluated the effect of suppressing tumor growth by sequentially comparing the tumor diameter with that of the control group. The mean temperature of the heated tumors was 60.2 +/- 1.8 degrees C. The tumor cells were constricted, and chromatin of nuclei had shrunk immediately after heating. The heat-injury area that contained the tumors was negative for NADH diaphorase activity. After 3 days, the tumor cells in the heat-injury area became positive for TUNEL staining, which detects cell death. At 7 days, the mean tumor diameters were significantly smaller in the heating group than in the control group (6.15 +/- 0.47 mm vs 16.89 +/- 2.69 mm; P < 0.05). This Device, utilizing heat energy induced by ferromagnetic metal under an AMF, appears useful as local thermotherapy for human liver cancer.

  • Novel tumor-Ablation Device for liver tumors utilizing heat energy generated under an alternating magnetic field
    Journal of Gastroenterology and Hepatology, 2008
    Co-Authors: Koichi Sato, Yuji Watanabe, Atsushi Horiuchi, Shungo Yukumi, Takashi Doi, Motohira Yoshida, Yuji Yamamoto, Tsunehiro Maehara, Takashi Naohara, Kanji Kawachi
    Abstract:

    BACKGROUND AND AIMS We have developed a novel tumor-Ablation Device for liver tumors utilizing heat energy induced by magnesium ferrite (MgFe(2)O(4)) particles under an alternating magnetic field (AMF) produced by electric currents. This novel Device can repeatedly heat liver tumors at lower temperature than usual heating Devices, such as radiofrequency Ablation therapy, with slight infliction of pain. This study assesses its heating effect on rat liver tumors as local therapy. METHOD The small needle was manufactured from MgFe(2)O(4) particles by sintering at 1100 degrees C. After a MgFe(2)O(4) needle was inserted into liver tumors comprising of dRLh-84 cells, the tumors were heated for 30 min under an AMF. We examined cellular activity by using nicotinamide adenine dinucleotide (NADH) diaphorase staining and terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick-end labeling (TUNEL) staining, and evaluated the effect of suppressing tumor growth by sequentially comparing the tumor diameter with that of the control group. RESULTS The mean temperature of the heated tumors was 60.2 +/- 1.8 degrees C. The tumor cells were constricted, and chromatin of nuclei had shrunk immediately after heating. The heat-injury area that contained the tumors was negative for NADH diaphorase activity. After 3 days, the tumor cells in the heat-injury area became positive for TUNEL staining, which detects cell death. At 7 days, the mean tumor diameters were significantly smaller in the heating group than in the control group (6.15 +/- 0.47 mm vs 16.89 +/- 2.69 mm; P < 0.05). CONCLUSION This Device, utilizing heat energy induced by ferromagnetic metal under an AMF, appears useful as local thermotherapy for human liver cancer.

Gerald D Dodd – One of the best experts on this subject based on the ideXlab platform.

  • effect of change in portal vein flow rates on hepatic Ablations created with a bipolar radiofrequency Ablation Device
    Radiology, 2017
    Co-Authors: Gerald D Dodd, Anthony C Lanctot, Kimberly E Lind
    Abstract:

    Our study shows that the size and shape of coagulation necrosis created by the bipolar radiofrequency Ablation Device tested in this study is not affected significantly by changes in portal vein blood flow rates.

  • Effect of Change in Portal Venous Blood Flow Rates on the Performance of a 2.45-GHz Microwave Ablation Device.
    Radiology, 2015
    Co-Authors: Gerald D Dodd, Anthony C Lanctot, Sarah M. Kreidler, Deborah H. Glueck
    Abstract:

    We have shown that the size and shape of coagulation created by a 2.45-GHz microwave Ablation Device is not significantly affected by physiological fluctuations in portal venous flow rates.

  • Effect of Change in Portal Venous Blood Flow Rates on the Performance of a 2.45-GHz Microwave Ablation Device.
    Radiology, 2015
    Co-Authors: Gerald D Dodd, Anthony C Lanctot, Sarah M. Kreidler, Deborah H. Glueck
    Abstract:

    To investigate the effect of change in portal venous blood flow rates on the size and shape of Ablations created by a 2.45-GHz microwave Ablation Device. This study was exempt from review by the institutional animal care and use committee. An in vitro bovine liver model perfused with autologous blood via the portal vein at five flow rates (60, 70, 80, 90, and 100 mL/min per 100 g of liver) was used to evaluate the effect of change in flow rates on the size and shape of coagulation created by a 2.45-GHz, 140-W microwave Ablation Device operated for 5 and 10 minutes. Three Ablations per Ablation time were conducted in each of 10 livers, with two livers perfused at each flow rate. Short- and long-axis diameters were measured from gross specimens, and volume and sphericity index were calculated. General linear mixed models that accounted for correlations within the liver were used to evaluate the effects of lobe, flow, and Ablation time on size and sphericity index of Ablations. Flow did not have a significant effect on the size or shape of coagulation created at 5 or 10 minutes (P > .05 for all tests). The mean short- and long-axis diameters and volume were 3.2 cm (95% confidence interval [CI]: 3.1, 3.3), 5.6 cm (95% CI: 5.4, 5.8), and 30.2 cm(3) (95% CI: 28.4, 32.1) for the 5-minute Ablations and 3.8 cm (95% CI: 3.7, 3.9), 6.5 cm (95% CI: 6.3, 6.7), and 49.3 cm(3) (95% CI: 47.5, 51.2), for the 10-minute Ablations, respectively. The mean sphericity index for both 5- and 10-minute Ablations was 34.4% (95% CI: 32%, 36.7%). Change in portal venous blood flow rates did not have an effect on the size and shape of Ablations created by a 2.45-GHz microwave Ablation Device.